Perceptive Advisors is an SEC-registered investment adviser based in New York, NY that reports managing 6 hedge funds on Form ADV. It reports $11.8 billion in regulatory assets under management. Its private funds, of all types, hold $11.7 billion in gross assets. Its disclosed U.S. stock holdings returned an estimated +25.8% 2026 YTD through Jun 30 (S&P 500: +9.5%), based on 13F filings. Over a longer period they returned an estimated +103.5% from Q3 2024 to Q2 2026, compared with +37.2% for the S&P 500, based on 13F filings.
- Regulatory assets under management
- $11.8 billionForm ADV Item 5.F
- Gross assets of private funds
- $11.7 billionAll private fund types, Form ADV
- Hedge funds managed
- 617 private funds in total
- Employees
- 49Form ADV Item 5.A
- Registration
- SEC-registered adviserCRD 154703
- Latest Form ADV
- 07/13/2026Disciplinary disclosures: yes, see SEC record
Estimated 13F portfolio performance
Estimated by AltMountain, derived from the firm’s public Form 13F filings. Not reported by the firm and not the return of any fund.
| Quarter | Est. 13F return | S&P 500 |
|---|---|---|
| Q2 2026 | +21.6% | +14.8% |
| Q1 2026 | +3.5% | -4.6% |
| Q4 2025 | +28.1% | +2.4% |
| Q3 2025 | +26.7% | +7.8% |
| Q2 2025 | +6.1% | +10.4% |
| Q1 2025 | -11.4% | -4.5% |
| Q4 2024 | -9.8% | +2.1% |
| Q3 2024 | +17.5% | +5.4% |
Estimate of the firm's disclosed long U.S. stock portfolio from its quarterly 13F filings, holding each quarter-end portfolio to the next quarter-end at prices implied by all 13F filers. It is a price return before dividends and fees, ignores shorts, options, bonds, cash and trading within the quarter, and is not the return of any fund. Disclosures
Manager of this firm? Report your fund’s actual net return, or email hello@altmountain.com to correct or remove this estimate. Removal requests from the firm are honored.
13F holdings as of Sep 30, 2026
The 50 largest of 99 share positions ($5,328,616,812) reported by Perceptive Advisors LLC on Form 13F for the quarter ended Sep 30, 2026, filed Nov 16, 2026. Shown as filed with the SEC. Original filing on SEC.gov ↗ The estimated return above runs through Jun 30, 2026; it is updated when the SEC publishes its complete data for the quarter.
Share of the reported 13F portfolio, ten largest positions
- Praxis Precision Medicines I11.07%
- Amylyx Pharmaceuticals Inc5.77%
- Spyre Therapeutics Inc5.48%
- Celcuity Inc4.75%
- Rhythm Pharmaceuticals Inc4.53%
- Roivant Sciences LTD4.47%
- Relay Therapeutics Inc4.31%
- Ascendis Pharma A/s4.15%
- Travere Therapeutics Inc3.91%
- Freenome Inc3.73%
| Stock | Value | % of 13F portfolio | Shares | Shares vs prior quarter |
|---|---|---|---|---|
| Praxis Precision Medicines I | $589,676,971 | 11.07% | 2,024,781 | -0.55% |
| Amylyx Pharmaceuticals Inc | $307,695,689 | 5.77% | 10,573,735 | +26.86% |
| Spyre Therapeutics Inc | $292,102,355 | 5.48% | 3,280,943 | -24.04% |
| Celcuity Inc | $252,857,219 | 4.75% | 3,179,794 | -0.54% |
| Rhythm Pharmaceuticals Inc | $241,137,320 | 4.53% | 2,532,556 | -2.08% |
| Roivant Sciences LTD | $238,105,844 | 4.47% | 6,510,961 | -19.47% |
| Relay Therapeutics Inc | $229,782,565 | 4.31% | 12,730,336 | -9.75% |
| Ascendis Pharma A/s | $221,341,629 | 4.15% | 971,521 | -16.52% |
| Travere Therapeutics Inc | $208,606,717 | 3.91% | 3,542,913 | -5.59% |
| Freenome Inc | $198,545,334 | 3.73% | 12,606,053 | New |
| Edgewise Therapeutics Inc | $168,014,249 | 3.15% | 4,138,282 | -5.39% |
| Inhibrx Biosciences Inc | $129,349,697 | 2.43% | 1,292,463 | -0.41% |
| Nurix Therapeutics Inc | $127,361,324 | 2.39% | 5,371,629 | +24.33% |
| Kardigan Inc | $120,959,764 | 2.27% | 8,200,662 | Unchanged |
| Meiragtx Hldgs PLC | $118,653,238 | 2.23% | 10,786,658 | Unchanged |
| Protagonist Therapeutics Inc | $117,865,615 | 2.21% | 836,579 | -14.80% |
| Immatics N.V | $98,744,410 | 1.85% | 11,246,516 | +8.31% |
| Zymeworks Inc | $93,920,321 | 1.76% | 3,545,501 | -15.24% |
| Oruka Therapeutics Inc | $89,317,114 | 1.68% | 1,072,363 | -20.27% |
| Revolution Medicines Inc | $88,898,106 | 1.67% | 433,100 | -17.91% |
| Solid Biosciences Inc | $86,085,050 | 1.62% | 11,906,646 | Unchanged |
| Biocryst Pharmaceuticals Inc | $85,814,727 | 1.61% | 10,301,888 | -0.07% |
| Avalyn Pharmaceuticals Inc | $76,219,183 | 1.43% | 2,675,296 | Unchanged |
| Tango Therapeutics Inc | $67,190,350 | 1.26% | 2,693,000 | -20.25% |
| Waters Corp | $59,317,650 | 1.11% | 135,000 | New |
| Repligen Corp | $52,374,217 | 0.98% | 272,456 | +9.77% |
| Artivion Inc | $48,202,458 | 0.90% | 2,112,290 | +21.59% |
| Alto Neuroscience Inc | $44,957,054 | 0.84% | 1,760,950 | +9.38% |
| Opus Genetics Inc | $43,560,000 | 0.82% | 9,000,000 | New |
| Lakefront Biotherapeutics NV | $36,837,278 | 0.69% | 1,242,404 | New |
| Abbott Laboratories | $34,118,587 | 0.64% | 345,225 | New |
| Blossomhill Therapeutics Inc | $33,779,278 | 0.63% | 1,812,193 | New |
| Orchestra Biomed Hldgs Inc | $31,333,909 | 0.59% | 5,037,606 | Unchanged |
| Corvus Pharmaceuticals Inc | $28,920,280 | 0.54% | 2,510,441 | -5.89% |
| Anteris Technologies Global | $26,615,949 | 0.50% | 3,425,476 | Unchanged |
| Adlai Nortye LTD | $26,568,032 | 0.50% | 1,660,502 | -7.40% |
| Minimed Group Inc | $25,700,400 | 0.48% | 1,320,000 | New |
| Cytomx Therapeutics Inc. | $25,209,126 | 0.47% | 9,268,061 | -11.22% |
| Rapport Therapeutics Inc | $24,337,891 | 0.46% | 724,342 | -6.34% |
| Septerna Inc | $22,205,453 | 0.42% | 567,479 | New |
| X4 Pharmaceuticals Inc | $21,316,424 | 0.40% | 7,350,491 | -7.35% |
| Enliven Therapeutics Inc | $21,201,275 | 0.40% | 462,506 | New |
| Sab Biotherapeutics Inc | $21,009,178 | 0.39% | 6,627,501 | Unchanged |
| Dyne Therapeutics Inc | $20,384,982 | 0.38% | 1,265,362 | -52.95% |
| Evolus Inc | $19,674,280 | 0.37% | 2,459,285 | Unchanged |
| Yarrow Bioscience Inc | $18,310,966 | 0.34% | 813,098 | New |
| Immunovant Inc | $17,543,474 | 0.33% | 519,345 | -61.74% |
| Scribe Therapeutics Inc | $16,938,876 | 0.32% | 920,341 | New |
| Nautilus Biotechnology Inc | $16,421,936 | 0.31% | 11,564,744 | -0.60% |
| Sutro Biopharma Inc | $15,640,329 | 0.29% | 970,846 | -25.60% |
Changes since Jun 30, 2026
Comparing the share counts in the two quarter-end filings: 23 new positions, 25 sold out, 11 increased, 40 reduced and 25 unchanged.
Number of positions (a count, not dollars)
- New positions23
- Increased11
- Unchanged25
- Reduced40
- Sold out25
New positions
| Stock | Value | Shares |
|---|---|---|
| Freenome Inc | $198,545,334 | 12,606,053 |
| Waters Corp | $59,317,650 | 135,000 |
| Opus Genetics Inc | $43,560,000 | 9,000,000 |
| Lakefront Biotherapeutics NV | $36,837,278 | 1,242,404 |
| Abbott Laboratories | $34,118,587 | 345,225 |
| Blossomhill Therapeutics Inc | $33,779,278 | 1,812,193 |
| Minimed Group Inc | $25,700,400 | 1,320,000 |
| Septerna Inc | $22,205,453 | 567,479 |
| Enliven Therapeutics Inc | $21,201,275 | 462,506 |
| Yarrow Bioscience Inc | $18,310,966 | 813,098 |
| Scribe Therapeutics Inc | $16,938,876 | 920,341 |
| Grail Inc | $13,579,169 | 96,911 |
| Veradermics Inc | $11,759,310 | 97,000 |
| Entera Bio LTD | $9,985,293 | 3,431,372 |
| Research Alliance Corp IV | $8,288,000 | 700,000 |
| Capricor Therapeutics Inc | $8,049,500 | 850,000 |
| Damora Therapeutics Inc Com SHS | $6,012,111 | 282,524 |
| Adarx Pharmaceuticals Inc | $5,982,000 | 300,000 |
| Olema Pharmaceuticals Inc | $4,968,000 | 575,000 |
| Ceribell Inc | $2,409,220 | 98,779 |
Sold out
| Stock | Value at Jun 30, 2026 | Shares held then |
|---|---|---|
| Nuvalent Inc | $195,192,368 | 1,580,505 |
| Apogee Therapeutics Inc | $173,625,838 | 1,308,113 |
| Ionis Pharmaceuticals Inc | $44,878,140 | 566,000 |
| Jazz Pharmaceuticals PLC | $40,964,900 | 170,000 |
| Sionna Therapeutics Inc | $39,810,950 | 905,000 |
| Corcept Therapeutics Inc | $34,639,576 | 398,385 |
| Damora Therapeutics Inc | $31,810,230 | 1,223,000 |
| Charles Riv Labs Intl Inc | $31,750,600 | 140,000 |
| Axsome Therapeutics Inc. | $28,993,007 | 118,450 |
| Tenax Therapeutics Inc | $24,735,000 | 1,700,000 |
| Intuitive Surgical Inc | $20,633,229 | 51,884 |
| Contineum Therapeutics Inc | $20,579,153 | 1,255,592 |
| Omada Health Inc | $17,259,943 | 786,330 |
| Oscar Health Inc | $11,408,000 | 400,000 |
| Boston Scientific Corp | $10,670,000 | 250,000 |
| Natera Inc | $9,416,329 | 34,689 |
| Research Alliance Corp III | $8,025,000 | 750,000 |
| Cullinan Therapeutics Inc | $7,766,164 | 426,478 |
| Phathom Pharmaceuticals Inc | $5,772,200 | 532,000 |
| Cogent Biosciences Inc | $4,685,873 | 121,082 |
Largest increases
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Inc | +2,238,853 | +26.86% | $307,695,689 | 10,573,735 |
| Nurix Therapeutics Inc | +1,051,207 | +24.33% | $127,361,324 | 5,371,629 |
| Artivion Inc | +375,000 | +21.59% | $48,202,458 | 2,112,290 |
| Immatics N.V | +863,060 | +8.31% | $98,744,410 | 11,246,516 |
| Crescent Biopharma Inc. | +500,000 | +241.61% | $10,314,284 | 706,942 |
| Guardant Health Inc | +28,673 | +69.38% | $12,485,200 | 70,000 |
| Repligen Corp | +24,244 | +9.77% | $52,374,217 | 272,456 |
| Xeris Biopharma Holdings Inc | +466,658 | +99.92% | $8,925,895 | 933,671 |
| Alto Neuroscience Inc | +151,057 | +9.38% | $44,957,054 | 1,760,950 |
| Uniqure NV | +66,773 | +19.87% | $9,730,996 | 402,773 |
| Axogen Inc | +32,688 | +13.22% | $11,737,600 | 280,000 |
Largest reductions
| Stock | Change in shares | Change | Value now | Shares now |
|---|---|---|---|---|
| Spyre Therapeutics Inc | -1,038,553 | -24.04% | $292,102,355 | 3,280,943 |
| Roivant Sciences LTD | -1,574,500 | -19.47% | $238,105,844 | 6,510,961 |
| Biogen Inc | -248,143 | -89.85% | $6,331,416 | 28,030 |
| Ascendis Pharma A/s | -192,200 | -16.52% | $221,341,629 | 971,521 |
| Unitedhealth Group Inc | -106,806 | -91.44% | $3,670,800 | 10,000 |
| Immunovant Inc | -838,038 | -61.74% | $17,543,474 | 519,345 |
| Relay Therapeutics Inc | -1,375,851 | -9.75% | $229,782,565 | 12,730,336 |
| Adaptive Biotechnologies Cor | -805,000 | -66.13% | $11,916,193 | 412,325 |
| Dyne Therapeutics Inc | -1,423,873 | -52.95% | $20,384,982 | 1,265,362 |
| Oruka Therapeutics Inc | -272,700 | -20.27% | $89,317,114 | 1,072,363 |
| Protagonist Therapeutics Inc | -145,300 | -14.80% | $117,865,615 | 836,579 |
| Revolution Medicines Inc | -94,500 | -17.91% | $88,898,106 | 433,100 |
| Tango Therapeutics Inc | -684,000 | -20.25% | $67,190,350 | 2,693,000 |
| Zymeworks Inc | -637,452 | -15.24% | $93,920,321 | 3,545,501 |
| Nuvectis Pharma Inc | -760,000 | -76.00% | $5,068,800 | 240,000 |
| Danaher Corp Del | -70,000 | -53.85% | $13,293,000 | 60,000 |
| Irhythm Holdings Inc | -110,000 | -49.16% | $12,930,644 | 113,766 |
| Travere Therapeutics Inc | -209,661 | -5.59% | $208,606,717 | 3,542,913 |
| Edgewise Therapeutics Inc | -235,692 | -5.39% | $168,014,249 | 4,138,282 |
| DBV Technologies S A | -516,816 | -31.26% | $13,365,640 | 1,136,534 |
Each list shows up to 20 positions, largest first by dollar amount. Changes compare two quarter-end snapshots, with the earlier share count adjusted for stock splits AltMountain detected. They do not show when, or at what price, anything was bought or sold.
From public Form 13F filings, not verified. Form 13F is filed up to 45 days after the quarter ends, so positions may have changed. It lists only certain long positions in U.S.-listed stocks and exchange-traded funds; options are not shown here, and short positions, most bonds, cash, non-U.S. securities and private investments are not reported at all, so a holding may be one side of a hedge. A filing covers the manager as a whole, not any single fund, and filings contain errors. This is not investment advice or a recommendation to buy or sell any security. Disclosures
Large ownership stakes (Schedule 13D and 13G)
| Company | Filing | Percent of class | Shares | Filed | Source |
|---|---|---|---|---|---|
| Yarrow Bioscience, Inc. | 13G amendment | 9.99% | 1,600,647 | Nov 16, 2026 | SEC.gov ↗ |
| Sutro Biopharma, Inc. | 13G amendment | 5.8% | 970,846 | Nov 16, 2026 | SEC.gov ↗ |
| Research Alliance Corporation IV | 13G amendment | 9% | 700,000 | Nov 16, 2026 | SEC.gov ↗ |
| Research Alliance Corporation III | 13G amendment | 0% | 0 | Nov 16, 2026 | SEC.gov ↗ |
| Orchestra BioMed Holdings, Inc. | 13G amendment | 8.15% | 6,537,606 | Nov 16, 2026 | SEC.gov ↗ |
| Nurix Therapeutics, Inc. | 13G amendment | 4.9% | 5,371,629 | Nov 16, 2026 | SEC.gov ↗ |
| Invivyd, Inc. | 13G amendment | 4.7% | 13,762,637 | Nov 16, 2026 | SEC.gov ↗ |
| Opus Genetics, Inc. | 13G amendment | 9.99% | 10,086,525 | Nov 16, 2026 | SEC.gov ↗ |
| Freenome, Inc. | 13G amendment | 11.3% | 12,606,053 | Nov 16, 2026 | SEC.gov ↗ |
| enGene Therapeutics Inc. | 13G amendment | 8.9% | 6,217,464 | Nov 16, 2026 | SEC.gov ↗ |
| Edesa Biotech, Inc. | 13G amendment | 4.2% | 563,239 | Nov 16, 2026 | SEC.gov ↗ |
| Amylyx Pharmaceuticals, Inc. | 13G amendment | 8.2% | 10,573,735 | Nov 16, 2026 | SEC.gov ↗ |
| Adagio Medical Holdings, Inc. | 13G amendment | 44.4% | 523,356 | Nov 16, 2026 | SEC.gov ↗ |
| Trinity Biotech plc | 13D amendment | 9.99% | 54,148,590 | Nov 10, 2026 | SEC.gov ↗ |
| Nautilus Biotechnology, Inc. | 13D amendment | 3.9% | 4,944,512 | Nov 3, 2026 | SEC.gov ↗ |
A firm files Schedule 13G (passive) or 13D (it may seek to influence the company) when it beneficially owns more than 5% of a class of a public company's shares. Each row is the firm's latest such filing for that company since Nov 14, 2025, exactly as filed, and counts shares held across the firm and its affiliates, not by any single fund. An amendment can report a stake that has fallen below 5%. Holdings may have changed since the filing date. Not verified by AltMountain. Showing the 15 most recent of 50 companies. Source: U.S. Securities and Exchange Commission, EDGAR.
Hedge funds filing Form D (3)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private equity funds filing Form D (5)
Matched to this firm by the fund names and related persons in each Form D. The list may be incomplete.
Private funds reported on Form ADV (20)
As reported in the adviser's Form ADV filed Aug 8, 2024. Funds also listed from Form D are shown above.
From SEC filings. Firm data comes from the SEC's Form ADV data as of Oct 2, 2026; performance estimates come from Form 13F. AltMountain has not verified this information, and it is not an offer, solicitation or recommendation. Full disclosures